NC-QUINTILES-NCTA
New Functionality Streamlines Workflow, Speeds Results and Improves Patient Safety
Quintiles today announced new functionality that improves laboratory management for investigator sites, delivered by its award-winning Quintiles Infosario® technology platform. Infosario seamlessly combines data, processes and Quintiles’ therapeutic expertise to enable faster, better-informed decisions across the drug development lifecycle. With Infosario, investigators and site personnel now have the ability to order tests, track samples and view results within one secure, online portal.
“The investigators working with Quintiles’ Global Laboratory network can now experience the benefits of streamlined communications, improved data accuracy and accelerated laboratory tests results,” said Thomas Wollman, Senior Vice President, Quintiles Global Laboratories and Cardiac Safety Services. “Our customers and investigators view the Infosario portal as a significant step forward in improving the speed and quality of laboratory management. This is another example of how we partner with our customers to improve their probability of success.”
The portal puts timely laboratory data at the fingertips of investigators, offering greater transparency and efficiency to tighten study timelines and improve patient safety through enhanced data quality. Investigators and site personnel can process electronic requisitions, review reports and respond to queries in an interactive format that cuts hours out of the process. The new functionality offers:
- Improved data quality through electronic requisitions and simplified medical reporting resolutions
- Improved sample tracking and traceability through electronic sample tracking
- Improved data consistency and fewer queries through the availability of online Standard Operating Procedures (SOPs) and training
- Reduced query resolution time through email alerts for unviewed medical reports or unanswered queries
More than a quarter of Quintiles’ investigators currently have access to the Infosario portal, and new functionality across Quintiles’ laboratory and clinical development services will be released in the near future to expand the platform to Quintiles’ entire network of more than 175,000 investigators. In an effort to continuously improve Infosario to meet customers’ needs, Quintiles is introducing enhancements in the coming months, including secure document exchange, investigator profile registrations and online training capabilities.
According to Michelle Kopfinger, an investigator site coordinator, “Quintiles is making proactive changes to help make lab management from a site perspective less burdensome. All of the lab reports are at the tip of your fingers and the data clarifications are resolved quicker through the system. It’s a great tool for managing lab reports.”
This announcement comes on the heels of Quintiles receiving the 2013 Informatica Innovation Award for “Enterprise Data Integration” for Infosario’s pioneering efforts to integrate clinical research and healthcare data across numerous institutions and at a scale never before accomplished in the biopharmaceutical industry. For more information, view the Infosario portal fact sheet and website . Demonstrations of Infosario will be available at the Drug Information Association (DIA) Annual Meeting on June 24-27 in Boston, Mass.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Contact:
Quintiles
Mari Mansfield, + 1-919-998-2639
Media Relations
mari.mansfield@quintiles.com
Mobile:
+1-919-259-3298
or
Karl Deonanan, +1-919-998-2789
Investor
Relations
InvestorRelations@quintiles.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum